Özlem Türeci
Özlem Türeci [ ˈœzlɛm ˈtyrɛdʒɪ ] (born March 6, 1967 in Lastrup ) is a German doctor , scientist and entrepreneur .
Türeci and her husband Uğur Şahin in 2008 founder of BioNTech , a company that in 2020 an mRNA -based vaccine against COVID-19 developed. She has been the medical director of BioNTech since 2018. She was the founder and CEO of Ganymed Pharmaceuticals from 2008 to 2016 . In addition, she is a private lecturer at the Johannes Gutenberg University in Mainz . Türeci is considered one of the leading figures in vaccine development against COVID-19.
Life and education
Özlem Türeci is the daughter of a surgeon from the Turkish town of Fındıklı , who came to Germany and worked in the Catholic hospital St. Elisabeth-Stift in Lastrup in the Lower Saxony district of Cloppenburg . She first grew up with her grandparents in Istanbul and from the age of four in Lastrup. Türeci visited a.o. the municipal grammar school in Bad Driburg and the Werner von Siemens grammar school in Bad Harzburg . She studied human medicine at the Saarland University in Homburg and received her doctorate in 1992 at the Saarland Medical Faculty. She received a habilitation and a Heisenberg grant from the German Research Foundation . Her research focuses on the identification and characterization of tumor- specific molecules and the development of immunotherapies against cancer. In 2002 he completed his habilitation at the Johannes Gutenberg University in Mainz in the field of molecular medicine .
Türeci met her future husband Uğur Şahin while working at the Saarland University Hospital in Homburg , where she completed her final year of study. The couple, who have a daughter, got married in 2002.
Works
Türeci was a co-founder and has been chairwoman of the German top-class research cluster for individualized immune intervention Ci3 of the Federal Ministry of Education and Research since 2011 and President of the Association for Cancer Immunotherapy (CIMT), the largest European association for cancer immunotherapy, since 2019 . She is internationally active as a lecturer.
Mainz University Medical Center
Türeci was an employee of the III. Medical Clinic of the University Medical Center Mainz and working group leader in the local Collaborative Research Center Immunology. Since 2002 she has been working as a private lecturer at the Mainz University Medical Center in the field of cancer immunotherapy. According to her own statement, she observed during this time "that science does not always arrive at the patient's bedside." for Translational Oncology (TRON), which was realized in 2001 in the form of a non-profit GmbH . This is a biopharmaceutical research institute that develops new diagnostics and drugs for the treatment of cancer and other diseases with a high unmet medical need. In 2018, TRON founded the "Helmholtz Institute for Translational Oncology (HI-TRON) Mainz" together with the DKFZ and the University of Mainz.
Ganymed Pharmaceuticals
Türeci founded Ganymed Pharmaceuticals in 2001 with her future husband Uğur Şahin . Ganymed and BioNTech, which was later founded, are spin-offs from Johannes Gutenberg University Mainz. This company developed the monoclonal antibody zolbetuximab, which is to be used against esophageal and stomach cancer . Türeci managed the company from 2008 to 2016 in the role of Chief Executive Officer (CEO) until the takeover. Before that, she was Chief Scientific Officer (CSO) from 2001 to 2008 . In 2016, the company was sold to Astellas Pharma for at least three-digit million euros and is now a subsidiary. After successful phase II studies , the drug will be in phase III as of 2020 .
Biontech
Türeci belonged 2008 to the founders of the biotechnology company BioNTech with headquarters in Mainz, whose medical CEO (Chief Medical Officer, CMO) has for the 2018th From 2009 to 2018 she was chair of the company's scientific advisory board . Biontech is focused on the development and manufacture of active immunotherapies for a patient-specific approach to the treatment of cancer and other serious diseases. As CMO, she is primarily responsible for clinical research and development. Biontech has been researching a vaccine against the infectious disease COVID-19 since January 2020 under the direction of Özlem Türeci and her husband Uğur Şahin, who is the company's CEO . She was responsible for the area of clinical studies for the development of the vaccine BNT162b2 (trade name Comirnaty ). Türeci is involved in more than 500 patents that she has registered with her company and partners.
Memberships
Türeci is a member of the American Society of Clinical Oncology (ASCO), the American Association for Cancer Research (AACR), the German Society for Immunology and the German Society for Hematology and Oncology .
Awards (selection)
- 1995: Vincenz-Czerny Prize of the German Society for Hematology and Oncology
- 1997: Calogero Pagliarello Research Prize from the Medical Faculty of Saarland University
- 2005: Georges Köhler Prize of the German Society for Immunology (together with Uğur Şahin)
- 2020: German Sustainability Award
- 2020: Financial Times Person of the Year (together with Uğur Şahin)
- 2021: Axel Springer Award (with Uğur Şahin)
- 2021: Large Cross of Merit with Star of the Order of Merit of the Federal Republic of Germany
- 2021: elected member of the European Molecular Biology Organization
- 2021: Princess of Asturias Prize in the “Scientific Research” category.
- 2021: Honorary doctorate from the Medical Faculty of the University of Cologne
- 2021: Entry in the Golden Book of the City of Cologne on September 17, 2021
- 2021: European Manager of the Year ,
- 2022: Paul Ehrlich and Ludwig Darmstaedter Prize
Publications (selection)
The PubMed database of the US National Library of Medicine lists over 130 publications in which Türeci has contributed, several of them as first or last author.
The database of the US National Library of Medicine lists 100 clinical studies and other publications in which Türeci has contributed, nine of them as the first author.
- 2021: Project Lightspeed: The way to the BioNTech vaccine - and to a medicine of tomorrow , together with Joe Miller and Uğur Şahin, Rowohlt Verlag, Hamburg 2021, ISBN 978-3-498-00277-0 .
- mRNA therapeutics
- S. Kreiter, A. Selmi, M. Diken, M. Koslowski, CM Britten, C. Huber, O. Tureci, U. Sahin: Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity. In: Cancer Res . tape 70 , no. 22 , 2010, p. 9031-9040 , PMID 21045153 (English).
- Programmable cell therapies
- T. Omokoko, P. Simon, O. Tureci, U. Sahin: Retrieval of functional TCRs from single antigen-specific T cells: Toward individualized TCR-engineered therapies. In: Oncoimmunology . tape 4 , no. 7 , 2015, PMID 26140230 (English).
- antibody
- Christiane R Stadler, Hayat Bähr-Mahmud, Laura M Plum, Kathrin Schmoldt, Anne C Kölsch, Özlem Türeci & Ugur Sahin: Characterization of the First-in-Class T-Cell Engaging Bispecific Single-Chain Antibody for Targeted Immunotherapy of Solid Tumors Expressing the Oncofetal Protein Claudin 6. In: OncoImmunology . 2015, doi : 10.1080 / 2162402X.2015.1091555 (English).
- Small molecule immunomodulators
- F. Vascotto, J. Petschenka, KC Walzer, M. Vormehr, M. Brkic, S. Strobl, R. Rösemann, M. Diken, S. Kreiter, Ö. Türeci, U. Sahin: Intravenous delivery of the toll-like receptor 7 agonist SC1 confers tumor control by inducing a CD8 + T cell response. In: Oncoimmunology . tape 8 , no. 7 , 2019, PMID 31143525 (English).
Web links
- Literature by and about Özlem Türeci in the catalog of the German National Library
- Johannes Göbel: Successful “Mainz Model” - The researcher couple Özlem Türeci and Uğur Şahin operate at a high level. Germany portal, March 26, 2015, accessed on June 9, 2020.
- Hanna Grabbe: What can it be, Özlem Türeci? Impulse - Network and Know-How for Entrepreneurs, November 27, 2011, accessed on June 9, 2020.
- Hatice Akyün : "We are vaccine" - About two scientists who not only give hope against the virus. Der Tagesspiegel , April 26, 2020, accessed on June 9, 2020.
- Steffen Klusmann , Thomas Schulz: “Germany will get enough vaccine.” Der Spiegel , January 1, 2021, accessed on January 4, 2021.
Individual evidence
- ↑ The management team. In: Homepage. BioNTech, accessed November 30, 2020 .
- ↑ Course catalog . Johannes Gutenberg University Mainz, accessed on November 30, 2020 .
- ↑ Privatdozentin Dr. Özlem Türeci. In: DFG - GEPRIS -. German Research Foundation, accessed November 30, 2020 .
- ↑ Lastruperin is Corona hope: Biontech founder Türeci. In: NDR. November 10, 2020, accessed November 30, 2020 .
- ↑ Elizabeth Dostert: Özlem Türeci: A Prussian Turk. In: SZ.de. January 4, 2021, accessed February 28, 2021 .
- ↑ Özlem Türeci, German doctor and entrepreneur. In: Munzinger, Internationales Biographisches Archiv 01/2021. January 5, 2021, accessed February 28, 2021 .
- ↑ Fabian Goebel: Biontech fake profiles announce corona vaccine. In: Mittelhessen.de. November 16, 2020, accessed February 28, 2021 .
- ↑ Reinhold Budde: Researcher lived in Bad Driburg. Accessed November 30, 2020 .
- ↑ Özlem Türeci: Detection of DNA polymorphisms using mini-satellite profiles in tumors and cell lines and investigations on casein kinase 2 in the oocyte of Xenopus laevis . ( dnb.de [accessed December 24, 2020]).
- ↑ Creating value through innovation. (PDF) In: Natur & Geist-Das Forschungsmagazin der Johannes Gutenberg University Mainz. Accessed November 30, 2020 .
- ↑ Tobias Stolzenberg: Two against cancer . In: Technology Review . No. 5 . Heise Verlag, Hanover 2018 ( heise.de [accessed October 26, 2020]).
- ↑ Kristina Läsker: The cancer researcher . In: Süddeutsche Zeitung . Edition Munich. January 14, 2009, p. 18 ( yumpu.com [accessed October 26, 2020]).
- ↑ Editor: BMBF LS5 Internet editorship: Cluster for Individualized Immune Intervention (Ci3) - BMBF top cluster. Accessed November 30, 2020 .
- ↑ Chairpersons - Cluster for Individualized Immune Intervention (Ci3) eV Accessed November 30, 2020 (American English).
- ↑ Who We Are. Association for Cancer Immunotherapy CIMT, accessed November 30, 2020 (American English).
- ↑ SPEAKERS. In: Science Asia Conference. Accessed November 30, 2020 .
- ↑ AG Sahin / Türeci. In: 14th Mainz Summer University. III. Medical Clinic and Polyclinic of Johannes Gutenberg University Mainz, accessed on November 30, 2020 .
- ↑ Priv.-Doz. Dr. med. Özlem Türeci, internist in 55131 Mainz, Obere Zahlbacher Strasse 63.Retrieved on November 30, 2020 .
- ↑ Clara Rodríguez Fernández-09/10/2017 7 mins Interviews: The Woman Developing the Next Generation of Cancer Immunotherapy. October 9, 2017, accessed November 30, 2020 (American English).
- ^ Ceremony for the anniversary of the University of Mainz. Accessed November 30, 2020 .
- ↑ About TRON. TRON - Translational Oncology at the University Medical Center of Johannes Gutenberg University Mainz, accessed on October 26, 2020 .
- ↑ Joe Miller: Ugur Sahin: The Immunologist Racing To Find a Vaccine . In: Financial Times . March 20, 2020 (English, ft.com [accessed October 26, 2020]).
- ↑ Successful "Mainz Model". March 26, 2015, accessed November 30, 2020 .
- ↑ Tobias Stolzenberg: Two against cancer . In: Heise Online . October 8, 2018 ( heise.de [accessed October 26, 2020]).
- ↑ Astellas buys Ganymede . In: transcript . October 28, 2016 ( transkript.de [accessed October 26, 2020]).
- ↑ O. Türeci, U. Sahin, H. Schulze-Bergkamen, Z. Zvirbule, F. Lordick: A Multicentre, Phase Iia Study of Zolbetuximab as a Single Agent in Patients With Recurrent or Refractory Advanced Adenocarcinoma of the Stomach or Lower Oesophagus: The Mono Study . In: Annals of Oncology: Official Journal of the European Society for Medical Oncology . tape 30 , no. 9 , June 26, 2019, ISSN 1569-8041 , p. 1487–1495 , doi : 10.1093 / annonc / mdz199 , PMID 31240302 , PMC 6771222 (free full text) - (English).
- ^ Antibody Shines in Advanced Gastric Cancer. June 5, 2016, accessed October 26, 2020 .
- ↑ A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma. In: ClinicalTrials. US National Library of Medicine, accessed October 26, 2020 .
- ↑ Form 20-F. US Securities and Exchange Commission , March 31, 2020, accessed November 10, 2020 .
- ^ Siegfried Hofmann, Katrin Terpitz: Vaccination against cancer . In: Handelsblatt . March 16, 2016, p. 16 .
- ↑ Biontech: At the speed of light to the first corona vaccine. In: Deutsche Welle. November 9, 2020, accessed on November 30, 2020 (German).
- ↑ Siegfried Hofmann, Christian Wermke: Ugur Sahin and Özlem Türeci: This medical couple is developing a Covid-19 vaccine. In: Handelsblatt . April 23, 2020 ( handelsblatt.com [accessed October 26, 2020]).
- ^ The Husband-and-Wife Team Behind the Leading Vaccine to Solve Covid-19. In: The New York Times. November 10, 2020, accessed on November 17, 2020 .
- ↑ Özlem Türeci's research while affiliated with Helmholtz Institute Mainz and other places. ResearchGate, accessed November 30, 2020 .
- ↑ MarketScreener: Özlem Türeci - Biography. Accessed December 14, 2020 .
- ^ Prize winner Vincenz-Czerny-Preis and their work. German Society for Hematology and Medical Oncology eV, accessed on November 30, 2020 .
- ↑ Georges Köhler Prize for Immunologists of the University Hospital - High distinction for Ugur Sahin and Özlem Türeci. In: Johannes Gutenberg University Mainz. September 21, 2005, accessed November 10, 2020 .
- ↑ Award ceremony 2020. In: German Sustainability Award . December 3, 2020, accessed December 14, 2020 .
- ↑ Clive Cookson, Joe Miller: FT People of the Year: BioNTech's Ugur Sahin and Ozlem Tureci. December 16, 2020, accessed December 24, 2020 (UK English).
- ↑ Axel Springer Award 2021 goes to Biontech founder . In: The world . December 23, 2020 ( welt.de [accessed December 23, 2020]).
- ↑ Federal President honors Özlem Türeci and Uğur Şahin with an Order of Merit. In: The Federal President. February 26, 2021, accessed February 26, 2021 .
- ↑ Biontech founders receive a Grand Cross of Merit from Steinmeier. February 26, 2021, accessed February 26, 2021 .
- ↑ Princess of Asturias Prize 2021
- ↑ City of Cologne press release of September 17, 2021: Entry in the Golden Book and honorary doctorate from the Medical Faculty, by Simone Winkelhog , accessed on September 17, 2021
- ↑ City of Cologne - Özlem Türeci and Uğur Şahin honored at the historic town hall of Cologne. Retrieved September 17, 2021 .
- ↑ co-founders of BioNTech win the European Business Press Award. In: economia.gr. September 12, 2021, accessed September 21, 2021 .
- ↑ Katalin Karikó, Özlem Türeci and Uğur Şahin receive the Paul Ehrlich and Ludwig Darmstaedter Prize 2022. September 21, 2021, accessed on September 21, 2021 .
- ^ PubMed. US National Library of Medicine, accessed November 30, 2020 .
personal data | |
---|---|
SURNAME | Türeci, Özlem |
BRIEF DESCRIPTION | German doctor, scientist and entrepreneur |
BIRTH DATE | March 6, 1967 |
PLACE OF BIRTH | Lastrup |